From TekinHealthHealthcare Tech Field Notes

Precision Neuroscience closed an oversubscribed $250 million Series D led by Pershing Square, the Ackman Oxman Institute and an undisclosed life-sciences investment fund, bringing its total raised since founding in 2021 to $430 million. Its Layer 7 Cortical Interface, a thin-film array of 1,024 electrodes that sits on the brain's surface without penetrating tissue, received FDA 510(k) clearance in 2025 for implantation up to 30 days. The company says it has completed more than 100 patient procedures across 18 medical institutions, including Mount Sinai, University of Chicago Medicine and Penn, and has a commercial partnership with Medtronic. Precision says the new funding will expand its clinical program and support further FDA review.

Why it's notable: It's one of the largest rounds yet for a brain-computer interface company, and one of the few with an FDA-cleared implant already in hospital use rather than confined to research settings, signaling BCI is moving from experimental to clinical faster than expected.

Johnson & Johnson received FDA de novo authorization on July 22, 2026 for its Ottava robotic surgical system, which builds four robotic arms into the operating table. The authorization covers upper-abdominal and other general surgery procedures including Roux-en-Y gastric bypass, sleeve gastrectomy, cholecystectomy, splenectomy, appendectomy, small bowel resection, fundoplication and hiatal hernia repair. The authorization came about six months after J&J filed. The company says it will launch with select U.S. customers first, and a U.S. trial in inguinal hernia repair is ongoing.

Why it's notable: Ottava is a second major competitor to Intuitive's da Vinci in soft-tissue surgery, after Medtronic's Hugo, which gives hospitals buying robots more choice on price and operating-room footprint.

On February 13, 2026, Medtronic announced FDA clearance of Stealth AXiS for spine surgery. The system combines surgical planning, navigation and robotic assistance in one platform. Its LiveAlign segmental tracking lets surgeons watch spinal motion and alignment during surgery without repeated imaging, the company says. Medtronic says the system is built for both hospitals and ambulatory surgery centers. It builds on Medtronic's 2018 purchase of Mazor Robotics and its StealthStation navigation line. The FDA later cleared it for cranial and ENT procedures in March 2026.

Why it's notable: Spine surgery is moving to outpatient centers. A single system that replaces separate navigation and robot units could make robotic spine surgery practical at ambulatory surgery centers, and it sharpens Medtronic's competition with Globus Medical.

On January 15, 2026, Boston Scientific agreed to buy Penumbra for $374 a share in cash and stock, valuing the company at about $14.5 billion. About $11 billion of the price is cash, funded from cash on hand and new debt. Penumbra makes mechanical thrombectomy systems that remove clots in stroke, pulmonary embolism and deep vein thrombosis, along with embolization devices. Boston Scientific says it will run Penumbra as a standalone business inside its cardiovascular group. The FTC issued a second request for more information in March 2026, Penumbra stockholders approved the deal in May, and as of July Boston Scientific still expected it to close in the second half of 2026.

Why it's notable: It is one of the largest medtech deals in years, and it puts a leading maker of stroke and clot-removal devices inside one of the biggest cardiovascular device companies, which could change how hospitals contract for these devices.

On December 3, 2025, Medtronic announced FDA clearance of its Hugo robotic-assisted surgery system for prostatectomy, nephrectomy and cystectomy. The company says these procedures account for about 230,000 US surgeries a year. The clearance was based on the Expand URO study, which Medtronic says met its primary safety and effectiveness endpoints. Hugo was already in use in more than 30 countries, and Medtronic says it expects general and gynecologic surgery indications to follow.

Why it's notable: Hugo is the first multi-port system from a large medtech company to enter the US soft-tissue robotics market dominated by Intuitive's da Vinci. That gives hospitals building robotic urology programs a second option from a major vendor.

Stereotaxis received FDA 510(k) clearance for GenesisX, its next-generation robotic magnetic navigation system. Physicians use it to steer a magnetic-tipped catheter from a computer during ablation for arrhythmias such as atrial fibrillation. Unlike earlier Stereotaxis systems, GenesisX has magnetic shielding built into the unit rather than the room walls, runs on standard power, needs no structural anchoring and has an 80% smaller cabinet. The company says this lets it be installed in existing cath labs without construction.

Why it's notable: Earlier versions needed a lab rebuilt around the robot, which was a big reason few hospitals adopted robotic navigation for ablation. Removing that requirement makes it a practical option for more EP programs.

Distalmotion received FDA 510(k) clearance for its Dexter robotic surgery system in total benign hysterectomy, removal of the ovaries and fallopian tubes, and other gynecologic procedures. It is Dexter's third U.S. indication, after inguinal hernia repair in October 2024 and gallbladder removal in May 2025. The company is targeting hospital outpatient departments and ambulatory surgery centers with a mobile robot that several specialties can share, and it says Dexter has been used in more than 2,000 procedures.

Why it's notable: Hysterectomy is one of the most common gynecologic operations and is moving to outpatient settings. A cheaper, shareable robot cleared for it adds competition to Intuitive's da Vinci for ambulatory surgery centers.